St. Jude Gets CE Mark for Epiducer - Analyst Blog

St. Jude Medical (STJ) recently announced that it received CE Mark for its Epiducer lead delivery system. This system is approved for neurostimulation therapy for managing chronic pain in the back or limbs, arising from unsuccessful back surgery. With the new system from St. Jude Medical, a single percutaneous entry point allows the entry of both S-Series perc-paddle leads and multiple lead arrays.

Prior to the Epiducer lead delivery system, which is intended to reduce procedural complexities, paddle leads were placed through laminotomy, an invasive surgical procedure involving removal of a part of vertebral bone. The new lead delivery system enables medical practitioners to efficiently place S-Series perc-paddle leads and/or multiple lead arrays used in spinal cord stimulation (SCS) therapy to manage chronic pain.

St. Jude Medical is a global medical device company with four operating segments: Cardiac Rhythm Management, Cardiovascular, Atrial Fibrillation, and Neuromodulation. St. Jude Medical’s neuromodulation segment’s net sales increased 16% on a year-over-year basis to $84.3 million in the reported quarter. The increase in segment revenue was driven by strong increase in volume and continued growth in the size of the neuromodulation market.

St. Jude Medical’s neuromodulation segment introduced several innovative products, including the Eon Mini, a small neurostimulator for chronic pain. The Brio neurostimulator received CE Mark approval. It is a small, long-lasting and rechargeable deep brain stimulation device (DBS) for treating the symptoms of Parkinson’s disease.

We currently have a Neutral rating on St. Jude Medical.

Read the full analyst report on "STJ"
Zacks Investment Research

Market News and Data brought to you by Benzinga APIs

To add Benzinga News as your preferred source on Google, click here.